Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of IN-A001 on Tacrolimus PK in Healthy Volunteers
NCT05353010Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegoprazan in gastroesophageal reflux disease (GERD), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration (Cmax) of Tacrolimus, Time to Maximum Plasma Concentration (Tmax) of Tacrolimus and 3 more. Status: unknown.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05353010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353010.